Joshua Schimmer
page
1
of
1
Gilead bets $11 billion on hepatitis in Pharmasset deal
Nov 21, 2011 17:02 EST
(Reuters) - Gilead Sciences Inc <GILD.O> struck a deal to buy biotechnology company Pharmasset Inc <VRUS.O> for about $11 billion in a huge and risky bet on the next generation of hepatitis C treatments.
Gilead bets $11 billion on hepatitis in Pharmasset deal
Nov 21, 2011 16:28 EST
(Reuters) - Gilead Sciences Inc <GILD.O> struck a deal to buy biotechnology company Pharmasset Inc <VRUS.O> for about $11 billion in a huge and risky bet on the next generation of hepatitis C treatments.
Targacept depression drug: high risk, high reward
Oct 03, 2011 16:32 EDT
BOSTON (Reuters) - Targacept Inc, a small drugmaker that began life inside the bowels of R.J. Reynolds Tobacco Co, has for years been using its understanding of nicotine to develop experimental treatments for depression, schizophrenia and, yes, smoking cessation.
Roche suspends dosing in diabetes drug trials
Sep 10, 2010 18:29 EDT
NEW YORK (Reuters) - Roche Holding has stopped giving patients its experimental diabetes treatment taspoglutide in late stage clinical trials due to a high rate of adverse reactions, marking a major blow to drug once seen to have $2 billion a year potential.
Drug safety data sends Affymax shares tumbling
Jun 21, 2010 15:25 EDT
Affymax shares fall to lowest point in over 3 years on anemia drug's late-stage safety data. Shares of Affymax fell to their lowest point in more than three years on Monday after the company reported safety data from ongoing late-stage studies of its anemia drug candidate Hematide that alarmed investors.
Genzyme faces FDA enforcement over plant issues
Mar 24, 2010 12:06 EDT
Genzyme Corp. said Wednesday the Food and Drug Administration will take enforcement action against the biotechnology company after a series of manufacturing problems stalled production of key drugs.
Genzyme faces FDA enforcement over plant issues
Mar 24, 2010 12:06 EDT
Genzyme faces FDA enforcement of inspections because of manufacturing issues. Genzyme Corp. said Wednesday the Food and Drug Administration will take enforcement action against the biotechnology company after a series of manufacturing problems stalled production of key drugs.
Ahead of the Bell: Amylin Pharmaceuticals
Jan 26, 2010 08:51 EST
Amylin Pharmaceuticals shares rise in premarket trading on diabetes drug regulatory outlook. Shares of Amylin Pharmaceuticals Inc. rose in premarket trading Tuesday as Wall Street considered the approval of a competitor's diabetes drug a good sign for the biotechnology company.
Biogen says Tysabri sales top $1 billion
Jan 12, 2010 17:52 EST
Biogen Idec says Tysabri sales top $1 billion, new patients grow 30 percent. Biogen Idec Inc. said Tuesday sales of its multiple sclerosis drug Tysabri topped $1 billion in 2009, and there were 30 percent more new patients taking the drug.
Analyst reaffirms Mannkind rating
Jan 11, 2010 12:09 EST
Rodman & Renshaw keep rating on MannKind after regulatory delay for inhaled insulin. Shares of MannKind Corp. bounced back from early losses Monday after the company said the Food and Drug Administration will take longer-than-expected to make a decision on the inhaled insulin Afrezza, formerly called Afresa.
Amgen shares dip on anemia drug concerns
Jan 07, 2010 16:51 EST
Amgen shares fall as FDA officials urge dosing studies for anemia drugs in kidney patients. Shares of Amgen Inc. fell Thursday over concerns that the Food and Drug Administration's plan to re-examine the safety of anemia drugs could pressure sales of leading anemia treatments Aranesp and Epogen.
Biotech stocks buck market's rally, slide in 2009
Dec 31, 2009 17:09 EST
Biotech stocks took a turn for the worse in 2009 as the major players dealt with regulatory, manufacturing and political issues as well as a deep recession, but their fortunes could turn in 2010 if they get added patent protection.
Biotech stocks buck market's rally, slide in 2009
Dec 31, 2009 17:09 EST
Regulatory, economic woes hurt biotech stocks in 2009, biosimilars a potential bright spot. Biotech stocks took a turn for the worse in 2009 as the major players dealt with regulatory, manufacturing and political issues as well as a deep recession, but their fortunes could turn in 2010 if they get added patent protection.
Amylin signs weight-loss drug deal with Takeda
Nov 04, 2009 07:14 EST
Amylin Pharmaceuticals Inc. says it could potentially receive more than $1 billion from a partnership with Japan's Takeda Pharmaceutical Co. on potential weight-loss treatments.
Amylin signs weight-loss drug deal with Takeda
Nov 02, 2009 17:30 EST
Amylin Pharmaceuticals signs weight-loss drug deal with Takeda potentially worth over $1B. Amylin Pharmaceuticals Inc. says it could potentially receive more than $1 billion from a partnership with Japan's Takeda Pharmaceutical Co. on potential weight-loss treatments.
J&J's Deal With Elan Hits A Possible Snag
Aug 07, 2009 11:09 EDT
More than five weeks after Johnson & Johnson announced it would invest $1.5 billion in Irish biotech Elan, the deal still has more twists in it than a pretzel.
page
1
of
1
